ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1303 • 2014 ACR/ARHP Annual Meeting

    Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity

    Khalid Abulaban1, Stacy P. Ardoin2, Marisa Klein-Gitelman3, Kelly A. Rouster-Stevens4, Michael Bennett5, Lori B. Tucker6, Kasha Wiley7, Shannen Nelson8, Karen Onel9, Nora G. Singer10, B Anne Eberhard11, Kathleen M. O'Neil12, Elizabeth B. Brooks13, Lawrence K. Jung14, Lisa F. Imundo15, Tracey Wright16, David Witte17, Jun Ying18, Prasad Devarajan5 and Hermine I. Brunner19, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 3Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, 4Pediatrics, Emory University School of Medicine, Atlanta, GA, 5Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 11Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 12Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 13Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Case Medical Center, Cleveland, OH, 14Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 15Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, 16Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 17Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 18University of Cincinnati, Cincinnati, OH, 19Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose :  LN is common in childhood-onset Systemic Lupus Erythematosus (cSLE). Kidney biopsies are impractical to assess the course of LN given their invasiveness and…
  • Abstract Number: 1295 • 2014 ACR/ARHP Annual Meeting

    Childhood-Onset Systemic Lupus Erythematosus:  Short-Term Treatment Response Rates in Proliferative Lupus Nephritis

    Andrea Human1, Simon Yu Tian2, Earl D. Silverman3 and Deborah M. Levy1, 1Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 2Rheumatology and Program of Child Health Evaluative Sciences, The Hospital for Sick Children, Institute of Medical Science, University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Proliferative Lupus Nephritis (PLN) occurs in up to 50% of patients with childhood-onset systemic lupus erythematosus (cSLE).  PLN is a significant source of morbidity and…
  • Abstract Number: 961 • 2014 ACR/ARHP Annual Meeting

    Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study

    John G. Hanly for the Systemic Lupus International Collaborating Clinics1, Aidan O'Keeffe2, Li Su3, Murray B. Urowitz4, Juanita Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha R Bernatsky8, Ann E. Clarke9, Daniel J. Wallace10, Joan T. Merrill11, David A. Isenberg12, Anisur Rahman13, Ellen M. Ginzler14, Paul Fortin15, Dafna D. Gladman4, Jorge Sanchez-Guerrero16, Michelle Petri17, Ian Bruce18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Cynthia Aranow21, Graciela S. Alarcon22, Barri Fessler23, Kristjan Steinsson24, Ola Nived25, Gunnar Sturfelt25, Susan Manzi26, Munther A. Khamashta27, Ronald F. van Vollenhoven28, Asad Zoma29, Manuel Ramos-Casals30, Guillermo Ruiz-Irastorza31, S. Sam Lim32, Thomas Stoll33, Murat Inanc34, Kenneth C. Kalunian35, Diane L. Kamen36, Peter Maddison37, Christine A. Peschken38, Søren Jacobsen39, Anca Askanase40, Jill P. Buyon41, Chris Theriault42, Kara Thompson42 and Vernon Farewell3, 1Division of Rheumatology, Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, Canada, 2MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutricion, Mexico city, Mexico, 6Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, Canada, 9Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, 10Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 11Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 13Centre for Rheumatology Research, University College London, London, United Kingdom, 14Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, 15Medicine, Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, Canada, 16Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 17Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 18Kellgren Centre for Rheum, Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 19Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 20Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, IL, 21Feinstein Institute for Medical Research, Mahasset, NY, 22Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 23Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 24Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, 25Department of Rheumatology, University Hospital Lund, Lund, Sweden, 26Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 27Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 28Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 29Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 30Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 31Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 32Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 33Kantonsspital Geissbergstr, Schaffhausen, Switzerland, 34Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 35UCSD School of Medicine, La Jolla, CA, 36Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 37Ysbyty Gwynedd Bangor, North Wales, United Kingdom, 38Rheumatology, University of Manitoba, Winnipeg, MB, Canada, 39Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 40Columbia University Medical Center, New York, NY, 41Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 42Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Improved immunosuppressive therapies have changed the treatment of lupus nephritis (LN) over the past decade. We examined the outcome of LN with current standard…
  • Abstract Number: 2990 • 2014 ACR/ARHP Annual Meeting

    Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study

    Javier Merayo-Chalico1, Elia Apodaca2, Ana Barrera-Vargas3, Jorge Alcocer-Varela3 and Diana Gómez-Martín3, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose:  Posterior reversible encephalopathy syndrome (PRES) is a well-known but rare complication in systemic lupus erythematosus (SLE) patients (
  • Abstract Number: 972 • 2014 ACR/ARHP Annual Meeting

    Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010

    Eric Y Yen1, Magda Shaheen2, Jennifer MP Woo3, Deborah K. McCurdy4 and Ram Raj Singh5, 1Pediatrics/Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2Charles R. Drew University of Medicine and Science, Los Angeles, CA, 3UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 4Pediatric Rheumatology, UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 5Medicine, UCLA Division of Rheumatology, Los Angeles, CA

    Title:  Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010Background/Purpose:  Many epidemiologic studies of systemic…
  • Abstract Number: 2738 • 2014 ACR/ARHP Annual Meeting

    Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis

    Ernesto J. Muñoz-Elías1, Kayla Norton1, John B. Grigg1, Liz Bromley1, David W. Peckham1, Eric J. Tarcha1, Jared Odegard2, James Qin2, Megan Yuasa3, Anne Stevens4, Wayel H. Abdulahad5, Galina Schmunk6, K. George Chandy6 and Shawn P. Iadonato1, 1Kineta Inc., Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA, 3Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, 4Seattle Children's Res Inst, Seattle Children's Hospital, Seattle, WA, 5Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 6Department of Physiology, Biophysics, and Surgery, UC Irvine, Irvine, CA

    Background/Purpose: The voltage-gated potassium channel Kv1.3 is a novel target for the treatment of autoimmune disorders including psoriatic and rheumatic diseases. ShK-186 is an exquisitely specific,…
  • Abstract Number: 962 • 2014 ACR/ARHP Annual Meeting

    A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis

    Jasvinder A. Singh1, Alomgir Hossain2, Ahmed Kotb2 and George Wells3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Ottawa, Ottawa, ON, Canada, 3Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada

    Background/Purpose To compare the risk of serious infections of immunosuppressive medications used for the treatment of lupus nephritis. Methods We performed an up to date…
  • Abstract Number: 1826 • 2014 ACR/ARHP Annual Meeting

    A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children

    Khalid Abulaban1, Michael Bennett2, Marisa Klein-Gitelman3, Stacy P. Ardoin4, Kelly A. Rouster-Stevens5, Lori B. Tucker6, Kasha Wiley7, Shannen Nelson8, Karen Onel9, Nora G. Singer10, Kathleen M. O'Neil11, Elizabeth Brooks12, B Anne Eberhard13, Lawrence K. Jung14, Lisa F. Imundo15, Tracey Wright16, David Witte17, Jun Ying18, Prasad Devarajan2 and Hermine I. Brunner19, 1Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Anne & Robert H Lurie Childrens Hospital of Chicago, Chicago, IL, 4Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, 5Pediatrics, Emory University School of Medicine, Atlanta, GA, 6Rheumatology, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Rheumatology, Cincinnati Children's Hospital Medical Center, c, OH, 8Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, 10Medicine, Division of Rhuematology, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 11Division of Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 12Rheumatology, Univ Hospitals of Cleveland, Cleveland, OH, 13Pediatrics/Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 14Pediatric Rheumatology, Children's National Medical Center, Washington, DC, 15Assoociate Professor of Pediatrics in Medicine - Rheumatoology, Columbia University Medical Center, New York, NY, 16Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, 17Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, 18University of Cincinnati, Cincinnati, OH, 19Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose Lupus Nephritis (LN) occurs in up to 80% of childhood-onset Systemic Lupus Erythematosus (cSLE) and it has a worse prognosis than adults. The current…
  • Abstract Number: 963 • 2014 ACR/ARHP Annual Meeting

    Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept

    Sarah Goglin1, David Wofsy2, Miriam G. Cisternas3 and Maria Dall'era1, 1Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3MGC Data Services, Carlsbad, CA

    Background/Purpose: The response to treatment of lupus nephritis is unpredictable. There is a need to identify clinical and biochemical characteristics that can predict treatment outcome…
  • Abstract Number: 1672 • 2014 ACR/ARHP Annual Meeting

    Facilitating the Medication Decision-Making process—What Do Patients with Lupus Nephritis Say?

    Ricahrd Shewchuk1, Haiyan Qu2, W. Winn Chatham2, Jinoos Yazdany3, Maria Dall'era4 and Jasvinder A. Singh5, 1University fo Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5University of Alabama and VA Medical Center, Birmingham, AL

    Background/Purpose: Low medication adherence in lupus nephritis puts patients at risk for poor outcomes, but to our knowledge, relatively little is known about what patients…
  • Abstract Number: 1667 • 2014 ACR/ARHP Annual Meeting

    Probability of 3 and 6 Month Complete Response in Lupus Nephritis

    Homa Timlin1, Michelle Petri1 and Laurence S Magder2, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis is a major cause of morbidity and mortality. The complete response rate is the most sensitive in detecting differences among therapeutic regimens.…
  • Abstract Number: 1666 • 2014 ACR/ARHP Annual Meeting

    The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus

    Hiroshi Kajiyama1, Keiju Hiromura2, Daisuke Ikuma1, Hidekazu Ikeuchi2, Hiroyuki Kurosawa3, Yoshiaki Hirayama3, Fumio Gondaira3, Masanori Hara4, Yoshihisa Nojima2 and Toshihide Mimura5, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 3Department of reagent research and development, Denka Seiken Co. Ltd., Niigata, Japan, 4Department of Pediatrics, Yoshida Hospital, Niigata, Japan, 5Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

    Background/Purpose Podocytes are glomerular visceral epithelial cells, whose number decrease due to death and/or detachment from capillary wall leads to severe proteinuria and end stage…
  • Abstract Number: 1663 • 2014 ACR/ARHP Annual Meeting

    Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis

    Angela Pakozdi1, Ravindra Rajakariar2, Michael Sheaff3 and Dev Pyne1, 1Rheumatology, Barts Health NHS Trust, London, United Kingdom, 2Renal Medicine, Barts Health NHS Trust, London, United Kingdom, 3Histopathology, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose  Lupus nephritis (LN) is a major complication of systemic lupus erythematous (SLE) and prevalence is estimated to be 50-60%. Recently, variable responses to induction…
  • Abstract Number: 1654 • 2014 ACR/ARHP Annual Meeting

    Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features

    Gabriela Hernandez-Molina1, Paola García-Trejo2, Norma Uribe3 and Antonio R. Cabral4, 1Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 3Pathology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

    Background/Purpose: To assess acute thrombotic microangiopathy (aTMA) and chronic vascular lesions (cTMA) in lupus nephropathy and to evaluate their association with extrarrenal lupus features, antiphospholipid…
  • Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting

    High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis

    Marco Ulises Martinez-Martinez1, Maria Daniela De Avila2, Mario Perales3, Lourdes Baranda4, Susana Román Acosta5, Jaime Antonio Borjas García5 and Carlos Abud-Mendoza1, 1Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 2Regional Unit Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 3Regional Unit of Rheumatology and Osteoporosis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 4Regional Unit of Rheumatology and Osteoposis, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 5Nephrology Department, Hospital Central y Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico

    Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology